{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:12:09Z","timestamp":1791857529046,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ruesch Center for the Cure of Gastrointestinal Cancers"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01009-1","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T10:06:08Z","timestamp":1751969168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Narayanan","family":"Sadagopan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Adam","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Smith","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetu","family":"Mukherji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Lindsay","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwu Ruth","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"1009_CR1","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh, D. Y. et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol. Hepatol. 9, 694\u2013704 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1009_CR2","doi-asserted-by":"publisher","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 3;401:1853-1865. Epub 2023 Apr 16. Erratum in: Lancet. 2023 Sep 16;402(10406):964. https:\/\/doi.org\/10.1016\/S0140-6736(23)01904-9. Erratum in: Lancet. 2024 Mar 23;403(10432):1140. https:\/\/doi.org\/10.1016\/S0140-6736(24)00545-2.","DOI":"10.1016\/S0140-6736(24)00545-2"},{"key":"1009_CR3","unstructured":"Survival Rates for Bile Duct Cancer. American Cancer Society. Updated March 1, 2023. Available online: https:\/\/www.cancer.org\/cancer\/types\/bile-duct-cancer\/detection-diagnosis-staging\/survival-by-stage.html (accessed September 1, 2024)"},{"key":"1009_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca, A. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22, 690\u2013701 (2021).","journal-title":"Lancet Oncol."},{"key":"1009_CR5","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt, A. N. J. et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N. Engl. J. Med. 384, 2394\u20132405 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1009_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan, T. et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N. Engl. J. Med. 381, 317\u2013327 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1009_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi, K. et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat. Med. 30, 257\u2013264 (2024).","journal-title":"Nat. Med."},{"key":"1009_CR8","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R. et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N. Engl. J. Med. 375, 2154\u20132164 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1009_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ygyno.2019.02.014","volume":"153","author":"KA Mesquita","year":"2019","unstructured":"Mesquita, K. A. et al. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. Gynecol. Oncol. 153, 416\u2013424 (2019).","journal-title":"Gynecol. Oncol."},{"key":"1009_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/hpb.12504","volume":"17","author":"M Potkonjak","year":"2015","unstructured":"Potkonjak, M. et al. Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. HPB (Oxf.). 17, 1119\u20131123 (2015).","journal-title":"HPB (Oxf.)."},{"key":"1009_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov. 9, 722\u2013737 (2019).","journal-title":"Cancer Discov."},{"key":"1009_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen, J. et al. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res. 79, 311\u2013319 (2019).","journal-title":"Cancer Res."},{"key":"1009_CR13","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1158\/0008-5472.CAN-21-0628","volume":"81","author":"RM Chabanon","year":"2021","unstructured":"Chabanon, R. M. et al. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer Res. 81, 2888\u20132902 (2021).","journal-title":"Cancer Res."},{"key":"1009_CR14","doi-asserted-by":"publisher","first-page":"73389","DOI":"10.18632\/oncotarget.12334","volume":"7","author":"YS Wang","year":"2016","unstructured":"Wang, Y. S. et al. LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors. Oncotarget 7, 73389\u201373401 (2016).","journal-title":"Oncotarget"},{"key":"1009_CR15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen, J. et al. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov. 5, 752\u2013767 (2015).","journal-title":"Cancer Discov."},{"key":"1009_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s12276-023-00979-1","volume":"55","author":"J Kwon","year":"2023","unstructured":"Kwon, J., Lee, D. & Lee, S. A. BAP1 as a guardian of genome stability: implications in human cancer. Exp. Mol. Med. 55, 745\u2013754 (2023).","journal-title":"Exp. Mol. Med."},{"key":"1009_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","volume":"10","author":"AN Boscoe","year":"2019","unstructured":"Boscoe, A. N., Rolland, C. & Kelley, R. K. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J. Gastrointest. Oncol. 10, 751\u2013765 (2019).","journal-title":"J. Gastrointest. Oncol."},{"key":"1009_CR18","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI90644","volume":"127","author":"G Kohanbash","year":"2017","unstructured":"Kohanbash, G. et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J. Clin. Invest. 127, 1425\u20131437 (2017).","journal-title":"J. Clin. Invest."},{"key":"1009_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","volume":"18","author":"CJ Pirozzi","year":"2021","unstructured":"Pirozzi, C. J. & Yan, H. The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 18, 645\u2013661 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1009_CR20","doi-asserted-by":"publisher","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","volume":"9","author":"PL Sulkowski","year":"2017","unstructured":"Sulkowski, P. L. et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci. Transl. Med. 9, eaal2463 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1009_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2018.04.555","volume":"149","author":"Y Drew","year":"2018","unstructured":"Drew, Y. et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC). Gynecol. Oncol. 149, 246\u2013247 (2018).","journal-title":"Gynecol. Oncol."},{"key":"1009_CR22","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao, S. et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 23, 3711\u20133720 (2017).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"1009_CR23","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2023.41.16_suppl.2619","volume":"41","author":"M Iglesia","year":"2023","unstructured":"Iglesia, M. et al. STK11 alterations as predictive biomarkers of resistance to immune checkpoint inhibitors in multiple cancers with mismatch repair gene alterations. JCO 41, 2619\u20132619 (2023).","journal-title":"JCO"},{"key":"1009_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.20517\/cdr.2021.146","volume":"5","author":"R Summey","year":"2022","unstructured":"Summey, R. & Uyar, D. Ovarian cancer resistance to PARPi and platinum-containing chemotherapy. Cancer Drug Resist. 5, 637\u2013646 (2022).","journal-title":"Cancer Drug Resist."},{"key":"1009_CR25","doi-asserted-by":"publisher","first-page":"S923","DOI":"10.1016\/j.annonc.2024.08.1567","volume":"35","author":"W Park","year":"2024","unstructured":"Park, W. et al. Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum. Ann. Oncol. 35, S923\u2013S936 (2024).","journal-title":"Ann. Oncol."},{"key":"1009_CR26","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1200\/JCO.2023.41.16_suppl.4113","volume":"41","author":"V Sahai","year":"2023","unstructured":"Sahai, V. et al. Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02. JCO 41, 4113\u20134113 (2023).","journal-title":"JCO"},{"key":"1009_CR27","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1200\/JCO.2023.41.16_suppl.4099","volume":"41","author":"E Tsang","year":"2023","unstructured":"Tsang, E., O\u2019Kane, G., Knox, J. & Chen, E. A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma. JCO 41, 4099\u20134099 (2023).","journal-title":"JCO"},{"key":"1009_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/oncolo\/oyae163","volume":"29","author":"A Mohan","year":"2024","unstructured":"Mohan, A. et al. PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma. Oncologist 29, 725\u2013730 (2024).","journal-title":"Oncologist"},{"key":"1009_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1009_CR30","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01009-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T10:06:12Z","timestamp":1751969172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01009-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01009-1","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}